Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?

While patients with type 2 diabetes mellitus (T2DM) are at increased risk to develop atrial fibrillation (AF), the mechanistic link between T2DM and AF-susceptibility remains unclear. Common co-morbidities of T2DM, particularly hypertension, may drive AF in the setting of T2DM. But direct mechanisms...

Descripción completa

Detalles Bibliográficos
Autores principales: Yurista, Salva R., Silljé, Herman H. W., Rienstra, Michiel, de Boer, Rudolf A., Westenbrink, B. Daan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945755/
https://www.ncbi.nlm.nih.gov/pubmed/31910841
http://dx.doi.org/10.1186/s12933-019-0984-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945755/
https://www.ncbi.nlm.nih.gov/pubmed/31910841
http://dx.doi.org/10.1186/s12933-019-0984-0

Ejemplares similares